“Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world. Symptomatic relief during the inflammation provides relief to the patients suffering from inflammatory autoimmune diseases. Although there are multiple anti-inflammatory drugs approved in the market, there is an indispensable need for better and novel anti-inflammatory therapeutics with lesser side effects and better efficacy.
The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth.
The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period.
Geographically, the market is segmented into four regions namely North America, Europe, Asia-Pacific and LAMEA. Among regions, North America holds the largest share accounting for 45.7% share of the global anti-inflammatory therapeutics market; however, the Asia-Pacific region is expected to exhibit the fastest growth during the forecast period. Major market players have adopted innovative strategies such novel drug development and product launch (novel and indication expansion) to increase their market presence. In 2014, AstraZeneca had five anti-inflammatory drugs in the final stages of drug development. These drugs are lesinurad, sifalimumab, anifrolumab, mavrilimumab and brodalumab. The companies have filed new patents to overcome the issues of patent expiries of their existing drugs, and to gain a prominent market share. The key companies profiled in this report include Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.
KEY MARKET BENEFITS:
The report provides a quantitative analysis of the current market and estimations during 2014 – 2020 that assist in identifying the prevailing market opportunities to capitalize.
Exhaustive analysis of the global anti-inflammatory therapeutics market by product type helps in understanding the types of therapeutics that are currently being used along with the categories that would gain prominence in the future.
Competitive intelligence (of leading manufacturers and distributors of anti-inflammatory therapeutics) helps in understanding the competitive scenario across the geographies.
Comprehensive analysis of factors that drive and restrict the growth of the global anti-inflammatory therapeutics market is provided.
SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.
The Country level analysis of anti-inflammatory therapeutics market conditions has been provided in this report.
KEY MARKET SEGMENTS:
The Global Anti-inflammatory Therapeutics Market is segmented below:
Global Anti-inflammatory Therapeutics Market By Indication
Arthritis
Respiratory diseases
Multiple sclerosis
Psoriasis
Inflammatory bowel disease
Other inflammatory diseases
Global Anti-inflammatory Therapeutics Market Drug Class
Anti-inflammatory Biologics
Non-Steroidal Anti-inflammatory drugs (NSAIDs)
Corticosteroids
Global Anti-inflammatory Therapeutics Market By Geography
North America
U.S.
Canada
Mexico
Europe
U.K.
Germany
France
Others
Asia-Pacific
China
Japan
India
Others
LAMEA
Latina America
Middle East and Africa
”
“CHAPTER 1 INTRODUCTION
1.1 Key Benefits
1.2 Key Market Segment
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition
3.2 Diverse approach of global regulators towards biosimilars
3.3 Safety issues of biosimilar drugs
3.4 Key Findings
3.4.1 Top impacting factors
3.4.2 Top winning strategies
3.4.3 Top investment pockets
3.5 Regulation and Reimbursement scenario
3.5.1 Regulations in United States
3.5.2 Regulations in Europe
3.5.3 Regulation in Asia
3.5.4 Comparison of Biosimilar medicine guidelines
3.6 Emerging economies a hotspot for biosimilars market
3.6.1 Brazil a treasure for the biosimilar manufacturers
3.6.2 China the bulkmarket for biosimilars
3.6.3 India an early adopter of biosimilars
3.7 Porters five force analysis
3.7.1 Higher bargaining of suppliers
3.7.2 Moderate bargaining power of buyers
3.7.3 Higher threats from substitutes due to lower switching cost
3.7.4 Lower threats from new entrants due to technological and political barriers
3.7.5 Higher competition among players
3.8 Value chain analysis
3.8.1 Primary activities
3.8.2 Supportive activities
3.9 Clinical trials
3.9.1 MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia
3.9.2 Efficacy Study of Two Formulations of Erythropoietin
3.9.3 Biosimilar RetacritTM (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anemia in Hematology and Oncology
3.9.4 An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1
3.10 Market Share analysis, 2014
3.11 Market Dynamics
3.11.1 Drivers
3.11.1.1 Growing pressure to reduce healthcare expenditure
3.11.1.2 Various blockbusters going off patent
3.11.1.3 High prevalence of chronic diseases among ageing population
3.11.1.4 Favorable intervention from the developing economies
3.11.1.5 Lower cost biosimilars drugs than original biologics
3.11.2 Restraints
3.11.2.1 High initial investment in research and development
3.11.2.2 Stringent regulations in developed economies to restrict investment
3.11.2.3 Medical Efficacy and Patient Safety
3.11.3 Opportunities
3.11.3.1 opportunities in Emerging economies
3.11.3.2 Emergence of bio-betters drugs
CHAPTER 4 GLOBAL MARKET BY TECHNOLOGY
4.1 Monoclonal Antibodies (MAb) Technology
4.1.1 Drivers
4.2 Recombinant DNA Technology (rDNA technology)
4.2.1 Drivers
4.2.2 Restraints & Opportunities
4.3 Chromatography
4.3.1 Protein sequencing
4.3.2 Liquid chromatography (LC)
4.3.3 Gas Chromatography (GC)
4.3.4 Drivers
4.4 Nuclear magnetic resonance (NMR) technology
4.4.1 Drivers
4.5 Electrophoresis
4.5.1 Drivers
4.5.2 Restraints & Opportunities
4.5.3 Gel Electrophoresis
4.5.4 Capillary Electrophoresis
4.6 MASS SPECTROMETRY
4.6.1 Drivers
4.6.2 Restraints
4.7 Western Blotting
4.7.1 Drivers
4.8 Bioassay
4.8.1 Drivers
4.8.2 Restraints
4.8.3 Techniques in Bioassay
CHAPTER 5 GLOBAL BIOSIMILARS MARKET BY PRODUCT
5.1 Human Growth Hormone
5.1.1 Key market trends
5.1.2 Key growth factors and opportunities
5.1.3 Market size & forecast
5.2 Insulin
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size & forecast
5.3 Interferon
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size & forecast
5.4 Granulocyte colony stimulating factor (G-CSF)
5.4.1 Key market trends
5.4.2 Key growth factors and opporunities
5.4.3 Market size & forecast
5.5 Erythropoietin
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size & forecast
5.6 Monoclonal antibodies
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size & forecast
5.7 Peptides
5.8 Others
5.8.1 Key market trends
5.8.2 Key growth factors and opportunity
CHAPTER 6 GLOBAL MARKET BY APPLICATIONS
6.1 Blood disorders
6.1.1 Drivers
6.1.2 Chemotherapy induce Anaemia
6.1.2.1 Drivers
6.1.2.2 RESTRAIN AND OPPORTINITIES
6.1.3 Hemophilia
6.1.4 Pulmonary embolism
6.1.4.1 DRIVER
6.2 Oncology diseases
6.2.1 Driver
6.2.2 Opportunities and restraints
6.2.3 Lungs cancer
6.2.4 Breast cancer
6.2.5 Cervical cancer
6.2.6 Colorectal cancer
6.2.7 Prostate cancer
6.2.8 Leukaemia
6.3 Chronic and autoimmune diseases
6.3.1 Diabetes
6.3.1.1 Drivers
6.3.2 Neutropenia
6.3.3 Multiple sclerosis
6.3.3.1 Drivers
6.3.3.2 Restraints and opportunities
6.3.4 Cystic Fibrosis
6.3.5 Rheumatoid arthritis (RA)
6.3.5.1 Drivers
6.3.5.2 Restraints
6.3.6 Acromegaly
6.3.6.1 drivers
6.3.7 Leprosy
6.4 Growth hormone deficiency
6.4.1 Drivers
6.5 Others
6.5.1 Gaucher disease
6.5.2 Osteoporosis
CHAPTER 7 GLOBAL MARKET BY SERVICES
7.1 Contract Research and Manufacturing Services
7.1.1 Drivers
7.1.2 Restraints & Opportunities
7.2 Clinical trials
7.2.1 Drivers & Restraints
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
CHAPTER 8 GLOBAL BIOSIMILARS MARKET BY GEOGRAPHY
8.1 North America
8.1.1 Key market trends
8.1.2 Key growth factors and opportunities
8.1.3 Market size & forecast
8.2 Europe
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size & forecast
8.3 Asia-Pacific
8.3.1 Key market trends
8.3.1.1 India
8.3.1.1.1 COMPETITIVE SCENARIO
8.3.1.2 China
8.3.1.2.1 COMPETITIVE SCENARIO
8.3.1.3 Australia
8.3.1.3.1 COMPETITIVE SCENARIO
8.3.2 Key growth factors and opporunities
8.3.3 Market size & forecast
8.4 LAMEA
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size & forecast
CHAPTER 9 KEY PRODUCTS AND RECENT ACTIVITIES
9.1 US
9.1.1 Hospira
9.1.1.1 Recent Activities
9.2 Europe
9.2.1 Stada Arzneimittel AG
9.2.1.1 Recent Activities
9.2.2 Hexal AG
9.2.3 Ratiopharm GmbH
9.2.4 Bioton
9.2.4.1 Recent Activities
9.2.5 Sandoz GmbH
9.2.5.1 Recent Activities
9.3 India
9.3.1 Dr.Reddy’s Labs (DRL)
9.3.1.1 Recent Activities
9.3.2 Intas Pharmaceuticals Ltd.
9.3.2.1 Recent Activities
9.3.3 Wockhardt Limited
9.3.3.1 Recent Activities
9.3.4 Biocon Limited
9.3.4.1 Recent Activities
9.3.5 Shantha Biotechnics Limited
9.3.5.1 Recent Activities
9.3.6 Reliance Life Sciences
9.4 Korea
9.4.1 Dong-A Pharmaceutical Co., Ltd
9.4.1.1 Recent Activities
9.4.2 LG Life Sciences
9.4.2.1 Recent Activities
9.4.3 Celltrion Pharm, Inc.
9.4.3.1 Recent Activities
9.5 Others
9.5.1 Teva Pharmaceutical Industries Ltd.
9.5.1.1 Recent Activities
CHAPTER 10 COMPANY PROFILES
10.1 Novartis (Sandoz)
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segment overview
10.1.4 Business performance
10.1.5 Key strategies
10.1.5.1 Primary Strategies: Clinical Trials
10.1.5.2 secondary Strategies: approval
10.1.6 SWOT analysis
10.2 Synthon Pharmaceuticals, Inc.
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segment overview
10.2.4 Key strategies
10.2.4.1 Primary Strategies: agreement
10.2.4.2 secondary Strategies: clinical trials
10.2.5 SWOT analysis
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Company Snapshot
10.3.3 Operating business segment overview
10.3.4 Business performance
10.3.5 Key strategies
10.3.5.1 Primary Strategies: approval
10.3.5.2 secondary Strategies: clinical trials
10.3.6 SWOT analysis
10.4 LG Life Sciences
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segment overview
10.4.4 Business performance
10.4.5 Key strategies
10.4.5.1 Primary Strategies: Collaboration
10.4.6 SWOT analysis
10.5 Celltrion
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segment overview
10.5.4 Business Performance
10.5.5 Key strategies
10.5.5.1 Primary Strategies: approval
10.5.6 SWOT analysis
10.6 Biocon
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segment overview
10.6.4 Business Performance
10.6.5 Key strategies
10.6.5.1 Primary Strategy: product launch
10.6.5.2 secondary Strategy: clinical trial
10.6.6 SWOT analysis
10.7 Hospira
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segment overview
10.7.4 Business performance
10.7.5 Key strategies
10.7.5.1 Primary Strategies: approval
10.7.5.2 secondary Strategies: clinical trials
10.7.6 SWOT analysis
10.8 Merck Serono (Merck Group)
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segment overview
10.8.4 Business performance
10.8.5 Key strategies
10.8.5.1 Primary Strategies: partnership and product launch
10.8.6 SWOT analysis
10.9 Biogen idec Inc.
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segment overview
10.9.4 Business performance
10.9.5 Key strategies
10.9.5.1 Primary Strategies: agreement and joint venture
10.9.6 SWOT analysis
10.10 Genentech (Roche Group)
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segment overview
10.10.4 Key strategies
10.10.4.1 Primary Strategies: Investment and license
10.10.5 SWOT analysis”
“TABLE 1 BIOSIMILARS MODERATE GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2 BIOSIMILARS RAPID GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3 BIOSIMILARS DIMINISHING GROWTH SCENARIO MARKET REVENUE BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4 BIOSIMILARS GUIDELINES ADOPTED BY REGIONS
TABLE 5 COMPARISON OF BIOSIMILAR MEDICINE GUIDELINES BY GEOGRAPHY (2013)
TABLE 6 BIOSIMILARS DEVELOPMENT 2013 (LATIN AMERICA)
TABLE 7 OFF GOING PATENTS 2013-2016
TABLE 8 PREVALENCE OF TOP TWO CHRONIC DISEASES (2013)
TABLE 9 BIOSIMILAR DEVELOPMENT STATUS (2013)
TABLE 10 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY PRODUCT TYPES 2014-2020 ($MILLION)
TABLE 11 PATENTS STATUS FOR THE HUMAN GROWTH HORMONE (BIOLOGICS)
TABLE 12 PATENT EXPIRATION STATUS FOR HUMAN GROWTH HORMONE DURING 2014-2020 (BIOLOGICS)
TABLE 13 GLOBAL HGH BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
TABLE 14 PATENTS APPROVED FOR INSULIN (BIOLOGICS)
TABLE 15 GLOBAL INSULIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY 2014-2020 ($MILLION)
TABLE 16 PATENTS APPROVED FOR INTERFERON (BIOLOGICS)
TABLE 17 PATENT EXPIRATION STATUS FOR INTERFERON DURING, 2014-2020 (BIOLOGICS)
TABLE 18 GLOBAL INTERFERON BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 19 PATENT EXPIRATION STATUS FOR G-CSF BIOSIMILARS DURING, 2014-2020 (BIOLOGICS)
TABLE 20 GLOBAL G-CSF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 21 PATENTS STATUS FOR ERYTHROPOIETIN (BIOLOGICS)
TABLE 22 PATENT EXPIRATION STATUS FOR ERYTHROPOIETIN DURING 2014-2020 (BIOLOGICS)
TABLE 23 GLOBAL ERYTHROPOIETIN BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 24 DRUG PATENT EXPIRATION FOR MONOCLONAL ANTIBODIES (BIOLOGICS)
TABLE 25 PATENT EXPIRATION STATUS FOR MONOCLONAL ANTIBODIES DURING, 2014-2020 (BIOLOGICS)
TABLE 26 GLOBAL MAB BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 27 GLOBAL PEPTIDE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014 -2020 ($MILLION)
TABLE 28 HIRUDIN BIOSIMILAR CANDIDATE STATUS
TABLE 29 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 30 GLOBAL BLOOD DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 31 GLOBAL ONCOLOGY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 32 GLOBAL CHRONIC AND AUTOIMMUNE DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 33 GLOBAL GROWTH HORMONE DEFICIENCY DISORDER BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 34 GLOBAL OTHER DISORDERS BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 35 GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 36 NORTH AMERICA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATION, 2014-2020 ($MILLION)
TABLE 37 BIOSIMILARS COMMERCIALLY AVAILABLE IN EUROPEAN UNION
TABLE 38 EUROPE BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 39 ASIA-PACIFIC BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)
TABLE 40 LAMEA BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET REVENUE, BY APPLICATIONS, 2014-2020 ($MILLION)”
“FIG. 1 TOP FACTORS IMPACTING BIOSIMILARS MARKET (2014-2020)
FIG. 2 TOP WINING STRATEGIES FOR BIOSIMILARS MARKET DURING (2010-2015)
FIG. 3 TOP WINING STRATEGIES BY SUBTYPE OF DEVELOPMENTS (2010-2015)
FIG. 4 TOP INVESTMENT POCKETS OF BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET PRODUCTS, 2014-2020
FIG. 5 KEY ACHIEVEMENTS FOR BIOSIMILAR REGULATORS (2010)
FIG. 6 REGULATORY FRAMEWORK FOR BIOSIMILAR PRODUCTS IN CHINA
FIG. 7 PORTERS FIVE FORCE ANALYSIS OF BIOSIMILARS MARKET
FIG. 8 VALUE CHAIN ANALYSIS OF BIOSIMILARS MARKET
FIG. 9 IMPACT ANALYSIS OF STAKEHOLDERS INVOLVED IN PRIMARY ACTIVITIES (2014-2020)
FIG. 10 MARKET SHARE ANALYSIS OF BIOSIMILARS MARKET (2014)
FIG. 11 IMPACT ANALYSIS OF PRODUCT MARKET SEGMENTS (2014, 2020-2025)
FIG. 12 NUMBER OF INCIDENCES OF DIABETES GLOBALLY, BY GEOGRAPHY (2000, 2011 & 2030)
FIG. 13 IMPACT ANALYSIS OF APPLICATION MARKET SEGMENTS (2014-2020-2025)
FIG. 14 IMPACT OF REGULATION ON VARIOUS GEOGRAPHIES, 2012
FIG. 15 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 16 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 17 SWOT ANALYSIS OF NOVARTIS (SANDOZ)
FIG. 18 SWOT ANALYSIS OF SYNTHON PHARMACEUTICALS
FIG. 19 NET REVENUE GENERATION BY GEOGRAPHY (2013)
FIG. 20 NET REVENUE GENERATION BY BUSINESSES (2013)
FIG. 21 SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 22 NET REVENUE GENERATION (2011-2013)
FIG. 23 SWOT ANALYSIS OF LG LIFE SCIENCES
FIG. 24 NET PROFIT DURING 2011-2013
FIG. 25 SWOT ANALYSIS OF CELLTRION
FIG. 26 REVENUE GENERATED BY BUSINESS UNITS (2013)
FIG. 27 SWOT ANALYSIS OF BIOCON
FIG. 28 NET SALES BY GEOGRAPHY (2013)
FIG. 29 NET SALES BY BUSINESS UNITS (2013)
FIG. 30 SWOT ANALYSIS OF HOSPIRA
FIG. 31 NET SALES BY GEOGRAPHY (2013)
FIG. 32 NET SALES BY BUSINESS UNITS (2013)
FIG. 33 SWOT ANALYSIS OF MERCK SERONO
FIG. 34 NET SALES BY GEOGRAPHY (2013)
FIG. 35 NET SALES BY BUSINESS UNITS (2013)
FIG. 36 SWOT ANALYSIS OF BIOGEN IDEC INC.
FIG. 37 SWOT ANALYSIS OF GENENTECH”
Novartis (Sandoz), Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono (Merck Group), Biogen idec Inc., Genentech (Roche Group)
